David Shaw’s Moderna MRNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.75M | Sell |
24,951
-641,581
| -96% | -$33.2M | ﹤0.01% | 3317 |
|
|
2026
Q1 | $33.9M | Sell |
666,532
-4,516,227
| -87% | -$211M | 0.02% | 854 |
|
|
2025
Q4 | $153M | Sell |
5,182,759
-963,615
| -16% | -$26.2M | 0.08% | 271 |
|
|
2025
Q3 | $159M | Sell |
6,146,374
-1,317,181
| -18% | -$36.7M | 0.09% | 247 |
|
|
2025
Q2 | $206M | Buy |
7,463,555
+1,827,404
| +32% | +$48.1M | 0.15% | 144 |
|
|
2025
Q1 | $160M | Buy |
5,636,151
+3,867,436
| +219% | +$137M | 0.14% | 163 |
|
|
2024
Q4 | $73.5M | Buy |
1,768,715
+1,509,591
| +583% | +$72.2M | 0.05% | 426 |
|
|
2024
Q3 | $17.3M | Buy |
+259,124
| New | +$23.8M | 0.01% | 1087 |
|
|
2024
Q2 | – | Sell |
-48,022
| Closed | -$6.08M | – | 4708 |
|
|
2024
Q1 | $5.12M | Sell |
48,022
-314,155
| -87% | -$31.7M | ﹤0.01% | 1870 |
|
|
2023
Q4 | $36M | Buy |
362,177
+303,845
| +521% | +$25.6M | 0.03% | 605 |
|
|
2023
Q3 | $6.03M | Sell |
58,332
-20,175
| -26% | -$2.25M | 0.01% | 1662 |
|
|
2023
Q2 | $9.5M | Sell |
78,507
-189,573
| -71% | -$25.3M | 0.01% | 1377 |
|
|
2023
Q1 | $41.2M | Sell |
268,080
-298,928
| -53% | -$49.3M | 0.04% | 508 |
|
|
2022
Q4 | $102M | Buy |
567,008
+294,842
| +108% | +$48.2M | 0.11% | 198 |
|
|
2022
Q3 | $32.2M | Buy |
272,166
+245,352
| +915% | +$37.2M | 0.04% | 597 |
|
|
2022
Q2 | $3.83M | Sell |
26,814
-1,227,130
| -98% | -$175M | ﹤0.01% | 2459 |
|
|
2022
Q1 | $216M | Buy |
1,253,944
+240,949
| +24% | +$40.6M | 0.2% | 78 |
|
|
2021
Q4 | $257M | Buy |
1,012,995
+259,232
| +34% | +$75.8M | 0.21% | 72 |
|
|
2021
Q3 | $290M | Sell |
753,763
-920,545
| -55% | -$340M | 0.26% | 51 |
|
|
2021
Q2 | $393M | Buy |
1,674,308
+1,616,152
| +2,779% | +$289M | 0.34% | 40 |
|
|
2021
Q1 | $7.62M | Sell |
58,156
-3,051,745
| -98% | -$442M | 0.01% | 1550 |
|
|
2020
Q4 | $325M | Buy |
3,109,901
+2,343,772
| +306% | +$237M | 0.29% | 50 |
|
|
2020
Q3 | $54.2M | Buy |
766,129
+455,804
| +147% | +$31.8M | 0.06% | 387 |
|
|
2020
Q2 | $19.9M | Buy |
310,325
+262,490
| +549% | +$14.4M | 0.02% | 780 |
|
|
2020
Q1 | $1.43M | Sell |
47,835
-327,503
| -87% | -$7.53M | ﹤0.01% | 2445 |
|
|
2019
Q4 | $7.34M | Buy |
+375,338
| New | +$6.66M | 0.01% | 1431 |
|
|
2019
Q3 | – | Sell |
-25,128
| Closed | -$368K | – | 3940 |
|
|
2019
Q2 | $368K | Buy |
+25,128
| New | +$540K | ﹤0.01% | 3222 |
|
Other funds holding MRNA
TP
David Shaw's MRNA Position: Q2 2026 in Review
David Shaw reduced its Moderna (MRNA) stake by 96% in Q2 2026, selling an estimated $33.2M and leaving 24,951 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3317.
David Shaw first reported a position in MRNA in Q2 2019 and has held it in 27 quarters since. The position peaked at $393M in Q2 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.
- David Shaw held 24,951 shares of Moderna worth $1.75M as of Q2 2026.
- David Shaw sold 641,581 Moderna shares in Q2 2026, an estimated $33.2M.
- Moderna made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3317 holding.
- David Shaw first reported a position in Moderna in Q2 2019 and has held it in 27 quarters since.
- David Shaw's Moderna position peaked at $393M in Q2 2021.
- 788 funds tracked by Wall St. Rank held Moderna as of Q2 2026.
Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.